DO HIV+ WOMEN ON PROTEASE INHIBITORS **DELIVER PRETERM? FINDINGS FROM A UK STUDY**

Graziella Favarato¹, Heather Bailey¹, Claire Townsend¹, Claire Thorne¹ on behalf of the UK and Ireland National Study on HIV in Pregnancy and Childhood (NSHPC) ¹Population, Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Background

- HIV-infected women on ritonavir-boosted protease inhibitor (PI/r) based ART regimens in pregnancy may be at higher risk of preterm delivery (PTD, <37weeks gestation) but evidence is inconsistent.
- Conflicting evidence around how timing of ART start, immune status (e.g. CD4 cell count) and interaction with other ART drugs may affect the risk
- The UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC) previously reported an increased PTD risk in women on combination ART (14%) versus mono/dual therapy (10%) delivering between 1990-2005 (Townsend et al, AIDS 2007)

Aims

- To assess whether antenatal PI/r-based, and in particular LPV/rbased regimens increase the risk of PTD compared with NNRTIbased regimens in women delivering between 2007 and 2015
- To examine whether ART at conception and first antenatal CD4 count affect these associations

Methods

- The NSHPC is a large national study that collects comprehensive population-based surveillance data on all HIV-positive pregnant women and their children seen for care in the UK and Ireland
- Inclusion criteria for analysis:
 - Singleton live births to diagnosed women delivering between 2007 and 2015
 - For women with repeated pregnancies, the most recent pregnancy was included
 - Women on NNRTI+2NRTI or PI/r+2NRTI who did not switch any ARV during pregnancy
- Logistic regression to examine the associations of PTD with LPV/r-, other PI/r- and NNRTI-based regimens adjusted for calendar year, maternal age, region of origin, parity, and stratified by CD4 count $(\leq 350, >350 \text{ cells/mm}^3)$ and ART at conception (yes, no)


The NSHPC currently receives core funding from Public Health England's HIV and STI Department and from the Infectious Diseases in Pregnancy Screening Programme. NSHPC Ethics: MREC/04/2/009

Results

Table 1 Maternal characteristics of pregnancies (n= 6037)

LPV/r+ NNRTI+2NRTI N (%) N (%) 1889 (31.1) 2368 (39 PTD (<37 GW) 284 (12) 169 (9.0) Year of Delivery 2007-2009 1192 (5 466 (24.7) 2010-2012 704 (37.3) 952 (40 2013-2015 719 (38.1) 224 (9. Maternal age at delivery 724 (30 <28 years 305 (16.2) 644 (27 28-32 years 415 (22.0) 575 (30.4) 568 (24 33-36 years 432 (18 594 (31.5) >36 years Parity (n=5945) 743 (31 506 (26.8) Primiparous Multiparous 1330 (70.4) 1615 (6 History of IDU 14 (0.7) 44 (1.9) First antenatal CD4 (cells/mm³) (n=5945) Median (IQR) 456 (325-610) 430 (30 CD4≤350 426 (28.9) 635 (34 1577 (83.5) 565 (23 ART at conception

Fig 1 Adjusted OR for PTD stratified by ART at conception and CD4 count (\leq 350 and \geq 350 cells/mm³)



Women with IDU history excluded

Acknowledgements

Thanks to all the respondents for the NSHPC. We also thank Pat Tookey, Mario Cortina-Borja, Helen Peters, Kate Francis, Anna Horn and Rebecca Sconza from the NSHPC team

2NRTI	Other PI/r+2NRT
39.0) 2.0)	N (%) 1816 (29.9) 176 (9.7)
50.3)	338 (18.6)
0.2)	637 (35.1)
.5)	841 (46.3)
0.6)	430 (23.7)
7.2)	455 (25.1)
4.0)	475 (26.2)
8.2)	456 (25.1)
1.4)	535 (29.5)
68.2)	1216 (67.0)
))	47 (2.6)
03-582)	441 (317-605)
4.1)	44 (30.8)
3.9)	948 (52.2)

Table 2 Factors associated with preterm deliveries in women (n=2385) on ART at conception stratified by CD4 count

	CD4≤350c/mm³			CD4>350c/mm ³		
	Ν	%PTD	aOR*(95%CI)	Ν	%PTD	aOR*(95%CI)
ART Regimen	504	13.7		1881	8.8	
NNRTI-+2NRTI	263	10.3	1.00	973	8.2	1.00
LPV/r+2NRTI	90	21.1	2.01(1.03, 3.91)	338	12.1	1.64(1.08, 2.47)
Other PI/r+2NRTI	151	15.2	2.05(1.07, 3.89)	570	7.9	0.98(0.66, 1.46)
Calendar year						
2007-2009	152	20.4	-	335	7.8	-
2010-2012	200	12.5	-	754	10.0	-
2013-2015	152	8.6	-	732	8.2	-
per 1yr increase	-	-	0.84(0.74, 0.95)	-	-	0.99(0.92, 1.07)
Maternal age						
<28years	87	12.6	1.00	270	6.3	1.00
28-32years	121	15.7	1.42(0.63, 3.22)	422	10.4	1.69(0.94, 3.05)
32-36years	142	12.0	1.00(0.43, 2.33)	582	7.6	1.11(0.61, 2.01)
>36years	154	14.3	1.22(0.54, 2.76)	607	10.1	1.64(0.92, 2.90)

Women with IDU history excluded (n=36); *Odds ratios all mutually adjusted + parity and region of origin.

- 1.01, 1.61])

Conclusion



• Overall, women on LPV/r-containing regimens but not those on other PI regimens had higher risk of PTD vs. women on NNRTIregimens. Increased PTD risk was also associated with first antenatal CD4≤350 (aOR 1.28 [95%CI 1.04, 1.58]), older age (>36 vs <28 years) (aOR 1.41 [1.05, 1.89]) and ART at conception (aOR 1.27)

• Stratified analysis suggested that women on LPV/r- (irrespective of CD4) and women on other PI (CD4 \leq 350 only) at conception were still at higher risk of PTD compared with women on NNRTIregimens at conception with similar CD4 count. (Fig 1 and Table 2).

• In this national UK/Ireland study, pregnant women on LPV/r-based regimens were at higher risk of PTD vs. those on NNRTI-based regimens but the association was only apparent in women on ART at conception. Results suggest that women on other PI/r- at conception may also be at higher risk if CD4 \leq 350.

